Anaveon Appoints Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

Anaveon, a late-stage biotechnology company based in Basel, Switzerland, announced the appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer on May 19, 2026. The company focuses on precision biologics designed to reprogram the immune system for treating autoimmune and inflammatory diseases.

D. and brings experience in immunology, translational medicine, and regulatory strategy for autoimmune and rare disease programs. D. and an MBA. She has worked in corporate strategy, deal-making, and value creation in immunology and neurology.

Ramanayake said the new executives will help advance the company's clinical development and immunology-focused pipeline. Jill Jene stated she will work to build strategic relationships and secure resources to deliver immuno-therapies for patients with autoimmune and inflammatory diseases.

Eric Zanelli said he is excited to lead Anaveon's scientific efforts at this stage of the company's development.